Rezvilutamide for metastatic hormone-sensitive prostate cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body and has not yet become resistant to hormone therapy.
- You are 18 years or older.
- You have not had previous treatments like chemotherapy or certain other hormone therapies for metastatic prostate cancer.
- You are in good overall health (able to perform daily activities with little or no help).
- You are willing to use effective contraception during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
This trial tests a new drug called Rezvilutamide in men who have had surgery for high-risk prostate cancer and are not getting radiation therapy. The goal is to see if the drug can help prevent the cancer from coming back.
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.